UNSPSC 51351704: Arzoxifene

This classification denotes a selective estrogen receptor modulator, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier E569WG6E60. European Medicines Agency schedules Arzoxifene in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00599MIG. Arzoxifene generally arises in the molecular formula C28H29NO4S. The term ARZOXIFENE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 13 no. 3, 1999, list 42.) Most nations schedule arzoxifene under HS 29349990 and SITC 51579.

As of Q4 2014, ARZOXIFENE remains the US FDA Preferred Term for this commodity. Arzoxifene bears US NLM identifiers UMLS ID C0677791 and NCI Concept Code C1805. SMILES: s1c(c(Oc2ccc(OCCN3CCCCC3)cc2)c2c1cc(O)cc2)c1ccc(OC)cc1.

UNSPSC 51351704 Arzoxifene is a Commodity code representing individual pharmaceutical active ingredients and finished products supplied through state and local health systems, procurement cooperatives, and institutional pharmacy networks. State and local governments procure under this code primarily through multistate cooperative purchasing alliances that aggregate demand across member jurisdictions to negotiate volume pricing and establish standing supply agreements with pharmaceutical manufacturers and authorized wholesalers. The work involves manufacturers or authorized distributors supplying pharmaceuticals meeting FDA compliance, current Good Manufacturing Practices (cGMP), and Drug Supply Chain Security Act (DSCSA) requirements, with vendors managing relationships across multiple authorized wholesale distribution channels, maintaining pricing flexibility across formats (flat price, net price tiers, WAC-minus structures), and providing comprehensive product data including National Drug Codes, SKUs, UPCs, strength, dosage form, and packaging configurations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products effective July 1, 2026, with proposals due March 26, 2026. The solicitation requires vendors to maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC), carry insurance including $5 million general liability and $2 million network security and privacy coverage, and accept a 3 percent administrative fee on all contract purchases plus performance penalties ranging from $200 to $1,500 per violation for late reporting or missed onboarding timelines. The contract term runs two years for new vendors with optional extensions at MMCAP's discretion, while incumbent vendors' amendments extend through June 30, 2028. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing for the contract term, and 5 percent each on administrative compliance, EDI capability, and acceptance of the 3 percent administrative fee.